Systematic review of patient-reported outcome instruments for gastroesophageal reflux disease symptoms

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 1, 2013, Pages 2-14

  Vakil, Nimish B ^a   Halling, Katarina ^b   Becher, Anja ^c   Rydén, Anna ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c OXFORD PHARMAGENESIS LTD   (United Kingdom)

Author keywords

Heartburn; Instruments; Patient reported outcomes; Questionnaires; Regurgitation

Indexed keywords

CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; DIAGNOSTIC PROCEDURE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GERD SYMPTOM ASSESSMENT SCALE; HUMAN; INTERNAL CONSISTENCY; MEDICAL LITERATURE; MEDICAL RESEARCH; NOCTURNAL GASTROESOPHAGEAL REFLUX DISEASE SYMPTOM SEVERITY AND IMPACT QUESTIONNAIRE; PATIENT REPORTED OUTCOME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTON PUMP INHIBOR ACID SUPPRESSION SYMPTOM TEST; PSYCHOMETRY; RATING SCALE; REVIEW; SYSTEMATIC REVIEW; TEST RETEST RELIABILITY;

ENDPOINT DETERMINATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; PATIENTS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SELF REPORT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84870919680     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328358bf74     Document Type: Review

References (56)

1. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastro-esophageal reflux disease (GERD) - a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920.
2. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 4:CD003245.
3. 2-receptor antagonists and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 4:CD002095.
4. Ruigómez A, Wallander MA, Johansson S, García Rodríguez LA. Irritable bowel syndrome and gastroesophageal reflux disease in primary care: is there a link? Dig Dis Sci 2009; 54:1079-1086.
5. Bolling-Sternevald E, Aro P, Ronkainen J, Storskrubb T, Talley NJ, Junghard O, et al. Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda study. Dig Dis 2008; 26:256-263.
6. Veldhuyzen van Zanten S, Armstrong D, Barkun A, Junghard O, White RJ, Wiklund IK. Symptom overlap in patients with upper gastrointestinal complaints in the Canadian confirmatory acid suppression test (CAST) study: further psychometric validation of the Reflux Disease Questionnaire. Aliment Pharmacol Ther 2007; 25:1087-1097.
7. Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, USA: Food and Drug Administration; 2009. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf [Accessed 9 December 2009].
8. EMA. Guideline on the evaluation of drugs for the treatment of gastroesophageal reflux disease. London, UK: Committee for Medicinal Products for Human Use of the European Medicines Agency; 2009. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 01/WC500052741.pdf [Accessed 9 September 2010].
9. Hinkle DE, Jurs SG, Wiersma W. Applied statistics for the behavioural sciences. 2nd ed. Boston: Houghton Mifflin; 1988.
10. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16:297-334.
11. Fayers PM, Machin D. Quality of life. The assessment, analysis and interpretation of patient reported outcomes. 2nd ed. Chichester:Wiley; 2007.
12. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998; 2:i-iv, 1-74.
13. Cohen J. Statistical power analysis for the behavioural sciences. New York: Academy Press; 1977.
14. Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33:1023-1029.
15. Johnsson F, Roth Y, Damgaard Pedersen NE, Joelsson B. Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire. Aliment Pharmacol Ther 1993; 7:81-86.
16. Jones R, Junghard O, Dent J, Vakil N, Halling K, Wernersson B, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009; 30:1030-1038.
17. Ofman JJ, Shaw M, Sadik K, Grogg A, Emery K, Lee J, et al. Identifying patients with gastroesophageal reflux disease: validation of a practical screening tool. Dig Dis Sci 2002; 47:1863-1869.
18. Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994; 69:539-547.
19. Rothman M, Farup C, Stewart W, Helbers L, Zeldis J. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 2001; 46:1540-1549.
20. Damiano A, Handley K, Adler E, Siddique R, Bhattacharyja A. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci 2002; 47:1530-1537.
21. Puhan MA, Guyatt GH, Armstrong D, Wiklund I, Fallone CA, Heels-Ansdell D, et al. Validation of a symptom diary for patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23:531-541.
22. Pare P, Meyer F, Armstrong D, Pyzyk M, Pericak D, Goeree R. Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. Can J Gastroenterol 2003; 17:307-312.
23. Junghard O, Wiklund I. Validation of a four-graded scale for severity of heartburn in patients with symptoms of gastroesophageal reflux disease. Value Health 2008; 11:765-770.
24. Zimmerman J. Validation of a brief inventory for diagnosis and monitoring of symptomatic gastro-oesophageal reflux. Scand J Gastroenterol 2004; 39:212-216.
25. Spiegel BM, Roberts L, Mody R, Harding G, Kothari-Talwar S, Kahrilas PJ, et al. The development and validation of a Nocturnal Gastro-oesophageal Reflux Disease Symptom Severity and Impact Questionnaire for adults. Aliment Pharmacol Ther 2010; 32:591-602.
26. Armstrong D, Veldhuyzen SJ, Chung SA, Shapiro CM, Dhillon S, Escobedo S, et al. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test. Can J Gastroenterol 2005; 19:350-358.
27. Shaw M, Dent J, Beebe T, Junghard O, Wiklund I, Lind T, et al. The reflux disease questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes 2008; 6:31-36.
28. Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96:52-57.
29. Bardhan KD, Stanghellini V, Armstrong D, Berghofer P, Gatz G, Monnikes H. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 891-898.
30. Monnikes H, Bardhan KD, Stanghellini V, Berghofer P, Bethke TD, Armstrong D. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004; 69:238-244.
31. Bardhan KD, Stanghellini V, Armstrong D, Berghofer P, Gatz G, Monnikes H. Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion 2004; 69:229-237.
32. Rubin G, Uebel P, Brimo-Hayek A, Hey KH, Doerfler H, Heading RC. Validation of a brief symptom questionnaire (ReQuest in Practice) for patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:846-851.
33. Torres-Quevedo R, Manterola C, Sanhueza A, Bustos L, Pineda V, Vial M. Diagnostic properties of a symptoms scale for diagnosing reflux esophagitis. J Clin Epidemiol 2009; 62:97-101.
34. Manterola C, Munoz S, Grande L, Bustos L. Initial validation of a questionnaire for detecting gastroesophageal reflux disease in epidemiological settings. J Clin Epidemiol 2002; 55:1041-1045.
35. Gomez-Escudero O, Remes-Troche JM, Ruiz JC, Pelaez-Luna M, Schmulson MJ, Valdovinos Diaz MA. Diagnostic usefulness of the Carlsson-Dent questionnaire in gastroesophageal reflux disease (GERD). Rev Gastroenterol Mex 2004; 69:16-23.
36. Pereira GI, Costa CD, Geocze L, Borim AA, Ciconelli RM, Camacho-Lobato L. Cross-cultural adaptation and validation for Portuguese (Brazil) of health related quality of life instruments specific for gastroesophageal reflux disease. Arq Gastroenterol 2007; 44:168-177.
37. Damiano A, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci 2003; 48:657-662.
38. Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol 2011; 106:421-431.
39. Armstrong D, Moayyedi P, Hunt RH, Lei Y, Bukoski M, White RJ. Resolution of persistent GERD symptoms after a change in therapy: EncomPASS - a cluster-randomized study in primary care [abstract]. Gastroenterol 2009; 136 (Suppl 1):M1870.
40. Hunt RH, Armstrong D, Moayyedi P, Lei Y, Bukoski M, White RJ. Improvement in sleep disturbance in patients with persistent GERD symptoms after a change in therapy: EncomPASS - a cluster-randomized study in primary care [abstract]. Gastroenterol 2009; 136 (Suppl 1): M1890.
41. Cao Y, Yan X, Ma X-Q, Wang R, Johansson S, Wallander M-A, et al. Validation of a survey methodology for gastroesophageal reflux disease in China. BMC Gastroenterology 2008; 8:37.
42. Li Y-M, Du J, Zhang H, Yu C-H. Epidemiological investigation in outpatients with symptomatic gastroesophageal reflux from the Department of Medicine in Zhejiang Province, east China. J Gastroenterol Hepatol 2008; 23:283-289.
43. Nocon M, Kulig M, Leodolter A, Malfertheiner P, Willich SN. Validation of the Reflux Disease Questionnaire for a German population. Eur J Gastroenterol Hepatol 2005; 17:229-233.
44. Nuevo J, Tafalla M, Zapardiel J. Validation of the Reflux Disease Questionnaire (RDQ) and Gastrointestinal Impact Scale (GIS) in patients with gastroesophageal reflux disease in the Spanish population. Gastroenterol Hepatol 2009; 32:264-273.
45. Pace F, Scarlata P, Casini V, Sarzi-Puttini P, Porro GB. Validation of the reflux disease questionnaire for an Italian population of patients with gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2008; 20:187-190.
46. Scheiman J, Herlitz J, Agewall S, Lanas A, Veldhuyzen van Zanten S, Nauclér E, et al. Esomeprazole 20mg and 40mg for 26 weeks reduces the frequency of upper gastrointestinal symptoms in patients taking low-dose acetylsalicylic acid for cardiovascular prevention: the Oberon trial [abstract]. Gut 2010; 59 (Suppl 3):A342.
47. Scheiman J, van Rensburg CJ, Uebel P, Douda L, Niezgoda K, Nauclér E, et al. Prevention of low-dose acetylsalicylic acid-associated gastric/duodenal ulcers with esomeprazole 20 mg and 40mg once daily in patients at increased risk of ulcer development: a randomized controlled trial (OBERON) [abstract M1895]. Gastroenterology 2009; 136 (Suppl 1):A70.
48. Scheiman J, Herlitz J, Agewall S, Lanas A, Veldhuyzen van Zanten S, Nauclér E, et al. Peptic ulcer prevention by esomeprazole 20mg and 40mg once daily in patients taking low-dose acetylsalicylic acid for secondary cardiovascular prevention [abstract]. Gut 2010; 59:A53.
49. Jones R, Patrikios T. The effectiveness of esomeprazole 40mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor. Int J Clin Pract 2008; 62:1844-1850.
50. Monnikes H, Pfaffenberger B, Gatz G, Hein J, Bardhan KD. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion 2005; 71:152-158.
51. Glatzel D, Abdel-Qader M, Gatz G, Pfaffenberger B. Pantoprazole 40mg is as effective as esomeprazole 40mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion 2007; 75 (Suppl 1):69-78.
52. Bardhan KD, Achim A, Riddermann T, Pfaffenberger B. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 25:1461-1469.
53. Stanghellini V, Armstrong D, Monnikes H, Berghofer P, Gatz G, Bardhan KD. Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion 2005; 71: 145-151.
54. Johnson DA, Levy BH III. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors. Expert Opin Pharmacother 2010; 11:1541-1548.
55. Boeckxstaens GE, Beaumont H, Mertens V, Denison H, Ruth M, Adler J, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139:409-417.
56. EMA. Reflection paper on the regulatory guidance for the use of healthrelated quality of life (HRQL) measures in the evaluation of medicinal products. London, UK: Committee for Medicinal Products for Human Use of the European Medicines Agency; 2005. Available at: http://www.ema.europa.eu/ema/ [Accessed 9 June 2006].